ABOUT US

QUALITY OF LIFE WITH A CHRONIC INFLAMMATORY DISEASE

Lipum AB (publ) is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully humanized antibody designed to give safer and more efficacious therapy by blocking a previously overlooked target molecule of the immune system.

Supported by solid pre-clinical data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis Lipum is exploring a range of other diseases with a high unmet medical need. We intend to show clinical proof of concept for SOL-116. This will enable a long-term sustainable business model through strategic partnerships.

Based in Umeå, an excellent life science cluster in Sweden, Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.

DIGITAL MATERIAL

Einar Pontén, CEO Lipum, presents the recent progress in bringing our lead candidate SOL-116 towards clinical verification At Biostock Life Science Summit, November 2020 (Time 14:02)

BioStock interview with Einar Pontén, CEO Lipum, at the LSX World Congress in London, February 2020. (Time 4:33)

Interview with Ulf Björklund, Chairman of the Board Lipum, at BIO-Europe 2019 in Hamburg. (Time 6:28)

ABOUT US